Oral anticoagulation in device-detected atrial fibrillation: effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes in the NOAH-AFNET 6 trial.

Lip GYH, Nikorowitsch J, Sehner S, Becher N, Bertaglia E, Blomstrom-Lundqvist C, Brandes A, Beuger V, Calvert M, Camm AJ, Chlouverakis G, Dan GA, Dichtl W, Diener HC, Fierenz A, Goette A, de Groot JR, Hermans A, Lubinski A, Marijon E, Merkely B, Mont L, Ozga AK, Rajappan K, Sarkozy A, Scherr D, Schnabel RB, Schotten U, Simantirakis E, Toennis T, Vardas P, Wichterle D, Zapf A, Kirchhof P

Open source

DOI
10.1093/eurheartj/ehae225
Published
2024 May 21
Container
European heart journal
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1093/eurheartj/ehae225,
  title = {Oral anticoagulation in device-detected atrial fibrillation: effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes in the NOAH-AFNET 6 trial.},
  author = {Lip GYH and Nikorowitsch J and Sehner S and Becher N and Bertaglia E and Blomstrom-Lundqvist C and Brandes A and Beuger V and Calvert M and Camm AJ and Chlouverakis G and Dan GA and Dichtl W and Diener HC and Fierenz A and Goette A and de Groot JR and Hermans A and Lubinski A and Marijon E and Merkely B and Mont L and Ozga AK and Rajappan K and Sarkozy A and Scherr D and Schnabel RB and Schotten U and Simantirakis E and Toennis T and Vardas P and Wichterle D and Zapf A and Kirchhof P},
  year = {2024},
  journal = {European heart journal},
  doi = {10.1093/eurheartj/ehae225},
  url = {https://doi.org/10.1093/eurheartj/ehae225}
}

RIS

TY  - JOUR
TI  - Oral anticoagulation in device-detected atrial fibrillation: effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes in the NOAH-AFNET 6 trial.
AU  - Lip GYH
AU  - Nikorowitsch J
AU  - Sehner S
AU  - Becher N
AU  - Bertaglia E
AU  - Blomstrom-Lundqvist C
AU  - Brandes A
AU  - Beuger V
AU  - Calvert M
AU  - Camm AJ
AU  - Chlouverakis G
AU  - Dan GA
AU  - Dichtl W
AU  - Diener HC
AU  - Fierenz A
AU  - Goette A
AU  - de Groot JR
AU  - Hermans A
AU  - Lubinski A
AU  - Marijon E
AU  - Merkely B
AU  - Mont L
AU  - Ozga AK
AU  - Rajappan K
AU  - Sarkozy A
AU  - Scherr D
AU  - Schnabel RB
AU  - Schotten U
AU  - Simantirakis E
AU  - Toennis T
AU  - Vardas P
AU  - Wichterle D
AU  - Zapf A
AU  - Kirchhof P
PY  - 2024
JO  - European heart journal
DO  - 10.1093/eurheartj/ehae225
UR  - https://doi.org/10.1093/eurheartj/ehae225
ER  - 

APA

GYH, L., J, N., S, S., N, B., E, B., C, B., A, B., V, B., M, C., AJ, C., G, C., GA, D., W, D., HC, D., A, F., A, G., JR, D. G., A, H., A, L., E, M., B, M., L, M., AK, O., K, R., A, S., D, S., RB, S., U, S., E, S., T, T., P, V., D, W., A, Z., & P, K. (2024). Oral anticoagulation in device-detected atrial fibrillation: effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes in the NOAH-AFNET 6 trial.. European heart journal. https://doi.org/10.1093/eurheartj/ehae225

Source records